Heat shock protein 90α in thymic epithelial tumors and non-thymomatous myasthenia gravis

References

• Detterbeck FC. Evaluation and treatment of stage I and II thymoma. J Thorac Oncol. 2010;5(10 Suppl 4):S318–12. doi:10.1097/JTO.0b013e3181f20dab.
   PubMedGoogle Scholar
• Marx A, Pfister F, Schalke B, Saruhan-Direskeneli G, Melms A, Strobel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev. 2013;12(9):875–884. doi:10.1016/j.autrev.2013.03.007.
   PubMed Web of Science ®Google Scholar
• Marx A, Strobel P, Badve SS, Chalabreysse L, Chan JKC, Chen G, de Leval L, Detterbeck F, Girard N, Huang J, et al. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol. 2014;9(5):596–611. doi:10.1097/JTO.0000000000000154.
   PubMed Web of Science ®Google Scholar
• Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, Shimosato Y. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994;44(5):359–367. doi:10.1111/j.1440-1827.1994.tb02936.x.
   PubMed Web of Science ®Google Scholar
• Bhora FY, Chen DJ, Detterbeck FC, Asamura H, Falkson C, Filosso PL, Giaccone G, Huang J, Kim J, Kondo K, et al. The ITMIG/IASLC thymic epithelial tumors staging project: a proposed lymph node map for thymic epithelial tumors in the forthcoming 8th edition of the TNM classification of malignant tumors. J Thorac Oncol. 2014;9(9 Suppl 2):S88–96. doi:10.1097/JTO.0000000000000293.
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–1036. doi:10.1016/S1474-4422(15)00145-3.
   PubMed Web of Science ®Google Scholar
• Schlesinger MJ. Heat shock proteins. J Biol Chem. 1990;265:12111–12114.
   PubMed Web of Science ®Google Scholar
• Khalil AA, Kabapy NF, Deraz SF, Smith C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim Biophys Acta. 2011;1816(2):89–104. doi:10.1016/j.bbcan.2011.05.001.
   PubMed Web of Science ®Google Scholar
• Vabulas RM, Wagner H, Schild H. Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol. 2002;270:169–184. doi:10.1007/978-3-642-59430-4_11.
   PubMed Web of Science ®Google Scholar
• Huang M-N, Yu H, Moudgil KD. The involvement of heat-shock proteins in the pathogenesis of autoimmune arthritis: a critical appraisal. Semin Arthritis Rheum. 2010;40(2):164–175. doi:10.1016/j.semarthrit.2009.10.002.
   PubMed Web of Science ®Google Scholar
• Shukla HD, Pitha PM. Role of hsp90 in systemic lupus erythematosus and its clinical relevance. Autoimmune Dis. 2012;2012:728605.
   PubMedGoogle Scholar
• Turturici G, Tinnirello R, Sconzo G, Asea A, Savettieri G, Ragonese P, Geraci F. Positive or negative involvement of heat shock proteins in multiple sclerosis pathogenesis: an overview. J Neuropathol Exp Neurol. 2014;73(12):1092–1106. doi:10.1097/NEN.0000000000000136.
   PubMed Web of Science ®Google Scholar
• Bao R, Lai C-J, Qu H, Wang D, Yin L, Zifcak B, Atoyan R, Wang J, Samson M, Forrester J, et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res. 2009;15(12):4046–4057. doi:10.1158/1078-0432.CCR-09-0152.
   PubMed Web of Science ®Google Scholar
• Mishra S, Singh S, Misra K. Restraining pathogenicity in candida albicans by taxifolin as an inhibitor of Ras1-pka pathway. Mycopathologia. 2017;182(11–12):953–965. doi:10.1007/s11046-017-0170-4.
   PubMed Web of Science ®Google Scholar
• Jensen MR, Schoepfer J, Radimerski T, Massey A, Guy CT, Brueggen J, Quadt C, Buckler A, Cozens R, Drysdale MJ, et al. NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res. 2008;10(2):R33. doi:10.1186/bcr1996.
   PubMed Web of Science ®Google Scholar
• Lee H, Saini N, Parris AB, Zhao M, Yang X. Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling. Int J Oncol. 2017;51(3):967–974. doi:10.3892/ijo.2017.4073.
   PubMed Web of Science ®Google Scholar
• Hendrickson AEW, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, et al. A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol. 2012;124(2):210–215. doi:10.1016/j.ygyno.2011.10.002.
   PubMed Web of Science ®Google Scholar
• Augello G, Emma MR, Cusimano A, Azzolina A, Mongiovi S, Puleio R, Cassata G, Gulino A, Belmonte B, Gramignoli R, et al. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma. Int J Cancer. 2019;144(10):2613–2624. doi:10.1002/ijc.31963.
   PubMed Web of Science ®Google Scholar
• Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, et al. Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018;28(6):605–610. doi:10.1097/CMR.0000000000000509.
   PubMed Web of Science ®Google Scholar
• McConnell JR, McAlpine SR. Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorg Med Chem Lett. 2013;23(7):1923–1928. doi:10.1016/j.bmcl.2013.02.014.
   PubMed Web of Science ®Google Scholar
• Janik S, Schiefer AI, Bekos C, Hacker P, Haider T, Moser J, Klepetko W, Müllauer L, Ankersmit HJ, Moser B, et al. HSP27 and 70 expression in thymic epithelial tumors and benign thymic alterations: diagnostic, prognostic and physiologic implications. Sci Rep. 2016;6(1):24267. doi:10.1038/srep24267.
   PubMedGoogle Scholar
• Janik S, Bekos C, Hacker P, Raunegger T, Ghanim B, Einwallner E, Beer L, Klepetko W, Müllauer L, Ankersmit HJ, et al. Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis. Oncotarget. 2017;8(29):47090–47102. doi:10.18632/oncotarget.17478.
   PubMedGoogle Scholar
• Huang J, Detterbeck FC, Wang Z, Loehrer PJ. SR. Standard Outcome Measures for Thymic Malignancies. J Thorac Oncol. 2010;5:2017–2023.
   Google Scholar
• Ruffini E, Detterbeck F, van Raemdonck D, Rocco G, Thomas P, Weder W, Brunelli A, Evangelista A, Venuta F, Khaled A, et al. Tumours of the thymus: a cohort study of prognostic factors from the European society of thoracic surgeons database. Eur J Cardiothorac Surg. 2014;46(3):361–368. doi:10.1093/ejcts/ezt649.
   PubMed Web of Science ®Google Scholar
• Zhu S, Wang J, He Y, Meng N, Yan G-R. Peptides/proteins encoded by non-coding RNA: a novel resource bank for drug targets and biomarkers. Front Pharmacol. 2018;9:1295. doi:10.3389/fphar.2018.01295.
   PubMed Web of Science ®Google Scholar
• Yallowitz A, Ghaleb A, Garcia L, Alexandrova EM, Marchenko N. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells. Cell Death Dis. 2018;9(6):621. Available from https://www.ncbi.nlm.nih.gov/pubmed/29799521.
   PubMedGoogle Scholar
• Tu Y, Tian Y, Wu Y, Cui S. Clinical significance of heat shock proteins in gastric cancer following hyperthermia stress: indications for hyperthermic intraperitoneal chemoperfusion therapy. Oncol Lett. 2018;15(6):9385–9391. https://www.ncbi.nlm.nih.gov/pubmed/29946371.
   PubMed Web of Science ®Google Scholar
• Gautam J, Bae YK, Kim J-A. Up-regulation of cathepsin S expression by HSP90 and 5-HT7 receptor-dependent serotonin signaling correlates with triple negativity of human breast cancer. Breast Cancer Res Treat. 2017;161(1):29–40. doi:10.1007/s10549-016-4027-1.
   PubMed Web of Science ®Google Scholar
• Drecoll E, Nitsche U, Bauer K, Berezowska S, Slotta-Huspenina J, Rosenberg R, Langer R. Expression analysis of heat shock protein 90 (HSP90) and Her2 in colon carcinoma. Int J Colorectal Dis. 2014;29(6):663–671. doi:10.1007/s00384-014-1857-3.
   PubMed Web of Science ®Google Scholar
• Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L, Dionigi G, Roukos DH. The role of heat shock proteins in cancer. Cancer Lett. 2015;360(2):114–118. doi:10.1016/j.canlet.2015.02.026.
   PubMed Web of Science ®Google Scholar
• Mumin NH, Drobnitzky N, Patel A, Lourenco LM, Cahill FF, Jiang Y, Kong A, Ryan AJ. Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer. BMC Cancer. 2019;19(1):102. doi:10.1186/s12885-019-5295-z.
   PubMedGoogle Scholar
• Cardillo MR, Ippoliti F. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis. Anticancer Res. 2006;26:3409–3416.
   PubMed Web of Science ®Google Scholar
• Breinig M, Mayer P, Harjung A, Goeppert B, Malz M, Penzel R, Neumann O, Hartmann A, Dienemann H, Giaccone G, et al. Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors. Clin Cancer Res. 2011;17(8):2237–2249. doi:10.1158/1078-0432.CCR-10-1689.
   PubMed Web of Science ®Google Scholar
• Crouch B, Murphy H, Belonwu S, Martinez A, Gallagher J, Hall A, Soo MS, Lee M, Hughes P, Haystead T, et al. Leveraging ectopic Hsp90 expression to assay the presence of tumor cells and aggressive tumor phenotypes in breast specimens. Sci Rep. 2017;7(1):17487. doi:10.1038/s41598-017-17832-x.
   PubMedGoogle Scholar
• Chen R, Chen S, Liao J, Chen X, Xu X. The mechanism of acetylcholine receptor in binding MuSK in myasthenia gravis and the role of HSP90 molecular chaperone. Am J Transl Res. 2016;8:1763–1768.
   PubMed Web of Science ®Google Scholar
• Ankersmit HJ, Lambers C, Zimmermann M, Hacker S, Moser B. Serendipity and technical considerations for the measurement of serum heat shock protein HSP27 in patients with COPD and lung cancer. Cell Stress Chaperones. 2015;20(5):727–728. doi:10.1007/s12192-015-0619-7.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Mueller T, Dieplinger B, Bekos C, Beer L, Hofbauer H, Dome B, Ankersmit HJ. Circulating heat shock protein 27 as a biomarker for the differentiation of patients with lung cancer and healthy controls–a clinical comparison of different enzyme linked immunosorbent assays. Clin Lab. 2014;60(6):999–1006. doi:10.7754/Clin.Lab.2013.130526.
   PubMed Web of Science ®Google Scholar
• Liu W, Li J, Zhang P, Hou Q, Feng S, Liu L, Cui D, Shi H, Fu Y, Luo Y, et al. A novel pan-cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic. Cancer Sci. 2019;110(9):2941–2959. doi:10.1111/cas.14143.
   PubMed Web of Science ®Google Scholar
• Garcia-Cardena G, Fan R, Shah V, Sorrentino R, Cirino G, Papapetropoulos A, Sessa WC. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature. 1998;392(6678):821–824. doi:10.1038/33934.
   PubMed Web of Science ®Google Scholar
• Bender AT, Silverstein AM, Demady DR, Kanelakis KC, Noguchi S, Pratt WB, Osawa Y. Neuronal nitric-oxide synthase is regulated by the hsp90-based chaperone system in vivo. J Biol Chem. 1999;274(3):1472–1478. doi:10.1074/jbc.274.3.1472.
   PubMed Web of Science ®Google Scholar
• Brouet A, Sonveaux P, Dessy C, Balligand JL, Feron O. Hsp90 ensures the transition from the early Ca2+-dependent to the late phosphorylation-dependent activation of the endothelial nitric-oxide synthase in vascular endothelial growth factor-exposed endothelial cells. J Biol Chem. 2001;276(35):32663–32669. doi:10.1074/jbc.M101371200.
   PubMed Web of Science ®Google Scholar
• Bardsen K, Nilsen MM, Kvaloy JT, Norheim KB, Jonsson G, Omdal R. Heat shock proteins and chronic fatigue in primary Sjogren’s syndrome. Innate Immun. 2016;22(3):162–167. doi:10.1177/1753425916633236.
   PubMed Web of Science ®Google Scholar
• Zuehlke AD, Moses MA, Neckers L. Heat shock protein 90: its inhibition and function. Philos Trans R Soc Lond B Biol Sci. 2018;373:1738. doi:10.1098/rstb.2016.0527.
   Google Scholar
• Ghasemi Y, Dabbagh F, Rasoul-Amini S, Borhani Haghighi A, Morowvat MH. The possible role of HSPs on Behcet’s disease: a bioinformatic approach. Comput Biol Med. 2012;42(11):1079–1085. doi:10.1016/j.compbiomed.2012.08.009.
   PubMed Web of Science ®Google Scholar
• Astarloa R, Martinez Castrillo JC. Humoral response to the human heat shock 60 kDa protein in myasthenia gravis. J Neurol Sci. 1996;135(2):182–183. doi:10.1016/0022-510X(95)00191-4.
   PubMed Web of Science ®Google Scholar
• Helgeland G, Petzold A, Hoff JM, Gilhus NE, Plant GT, Romi FR. Anti-heat shock protein 70 antibody levels are increased in myasthenia gravis and Guillain-barre syndrome. J Neuroimmunol. 2010;225(1–2):180–183. doi:10.1016/j.jneuroim.2010.04.024.
   PubMed Web of Science ®Google Scholar
• Cappello F, Marino Gammazza A, Zummo L, Conway de Macario E, Macario AJL. Hsp60 and AChR cross-reactivity in myasthenia gravis: an update. J Neurol Sci. 2010;292:117–118.
   PubMed Web of Science ®Google Scholar
• Borges TJ, Wieten L, van Herwijnen, Broere F, Martijn JC, Broere F, van der Zee R, Bonorino C. The anti-inflammatory mechanisms of Hsp70. Front Immunol. 2012;3:95. doi:10.3389/fimmu.2012.00095.
   PubMed Web of Science ®Google Scholar
• Levinson AI. Modeling the intrathymic pathogenesis of myasthenia gravis. J Neurol Sci. 2013;333(1–2):60–67. doi:10.1016/j.jns.2012.12.025.
   PubMed Web of Science ®Google Scholar
• Leopardi O, Naughten W, Giannulis I, Mirra M, Frigo B. HSP70 is selectively over-expressed in the blast cells of the germinal centres and paracortex in reactive lymph nodes. Histopathology. 2001;39(6):566–571. doi:10.1046/j.1365-2559.2001.01293.x.
   PubMed Web of Science ®Google Scholar
• Wang X, Chen M, Zhou J, Zhang X. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (Review). Int J Oncol. 2014;45(1):18–30. doi:10.3892/ijo.2014.2399.
   PubMed Web of Science ®Google Scholar
• Sun P, Garrison LP. Retrospective outcomes studies for orphan diseases: challenges and opportunities. Curr Med Res Opin. 2012;28(4):665–667. doi:10.1185/03007995.2012.673480.
   PubMed Web of Science ®Google Scholar
• Filosso PL, Yao X, Ahmad U, Zhan Y, Huang J, Ruffini E, Travis W, Lucchi M, Rimner A, Antonicelli A, et al. Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the international thymic malignancy interest group and the european society of thoracic surgeons databases. J Thorac Cardiovasc Surg. 2015;149(1):103–9.e2. doi:10.1016/j.jtcvs.2014.08.061.
   PubMed Web of Science ®Google Scholar